ISPOR and ISPE Publish Joint Real-World Evidence Transparency Position Statement

Published Sep 29, 2026
Both Societies Jointly Affirm that Transparency Is Fundamental to the Reproducibility, Credibility, and Usefulness of RWE

Lawrenceville, NJ, USA—September 29, 2026—ISPOR—The Professional Society for Health Economics and Outcomes Research and the International Society for Pharmacoepidemiology (ISPE) announced today that their societies have published a joint position statement on real-world evidence (RWE) transparency.

RWE is the clinical evidence obtained from analyzing real-world data regarding the use, potential benefits, and potential risks associated with a medical treatment, diagnostic, or program. It offers many benefits that are particularly useful for research that can be applied to healthcare decision making. Advantages include the availability of timely data at reasonable cost, large sample sizes that enable analysis of subpopulations and less common effects, and the representativeness of real-world practice and behaviors. While RWE offers tremendous potential, it also presents very real concerns that continue to cast shadows on its credibility.

Transparency in research enables the public and decision makers to trust the science that underpins RWE. Toward this goal, the societies have now released a joint RWE Transparency Position Statement affirming that transparency is fundamental to the reproducibility, credibility, and usefulness of RWE, and the criticality of intentional documentation throughout the study lifecycle.

ISPOR and ISPE have long collaborated together on initiatives related to RWE transparency. A notable collaboration is the RWE Registry that was launched in 2021as a simplified registration site especially for RWE and hypothesis evaluation of treatment effects including safety studies using secondary data. The RWE Registry is designed to promote a culture of transparent reporting for real-world evidence studies on treatment effects.

Researchers and other stakeholders who would like to endorse this statement can do so on the RWE Transparency Position Statement LinkedIn page.

Additional information can be found here:
RWE Transparency Initiative  |  RWE Transparency Position Statement  |  RWE Registry  |  About RWE

###

 

ABOUT ISPOR
ISPOR—The Professional Society for Health Economics and Outcomes Research
(HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field.
Website
 | LinkedIn  | X (@ispororg)  |  Bluesky  |  YouTube  |  Facebook  |  Instagram   

ABOUT ISPE
The International Society for Pharmacoepidemiology (ISPE) is an international organization dedicated to advancing the health of the public by providing a global forum for the open exchange of scientific information and for the development of policy, education, and advocacy for the field of pharmacoepidemiology, including such areas as pharmacovigilance, drug utilization research, comparative effectiveness research, and therapeutic risk management.

Explore Related HEOR by Topic


Related Stories

New Research and Policy Priorities Chart a Broader Role for HEOR

Oct 15, 2026

Value in Health announced today the publication of a new commentary that calls for expanding the role of health economics and outcomes research (HEOR) and increasing its impact on real-world decision making.

ISPOR Europe 2026 Plenaries Announced

Sep 30, 2026

ISPOR—The Professional Society for Health Economics and Outcomes Research (HEOR) announced details for its ISPOR Europe 2026 conference. The conference is the leading global event in Europe for health economics and outcomes research (HEOR) and is scheduled for 8-11 November in Vienna, Austria with the theme, “Shaping the Future of Access Through Science and Policy.”

New Study Sheds Light on QALY and Disability Debate

Sep 28, 2026

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a study showing no evidence that the use of quality-adjusted life years (QALYs) inherently disadvantages people with disabilities.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×